Therapeutic efficacy of aglepristone and mifepristone for pyometra in dogs

This study evaluates the therapeutic efficacy of injectable and oral antiprogestins, alone and in combination with misoprostol, for the treatment of canine pyometra. At the Veterinary College, Hebbal, Bengaluru, from September 2023 to August 2024, 24 female dogs diagnosed with pyometra were randomly assigned to four treatment groups: Group I (aglepristone 10 mg/kg s.c. on days 0, 1, and 7), Group II (aglepristone 10 mg/kg s.c. on days 0, 1, and 7, plus misoprostol 5 µg/kg orally b.i.d. on days 2 to 6), Group III (mifepristone 5 mg/kg orally b.i.d. on days 0, 1, and 7), and Group IV (mifepristone 5 mg/kg orally b.i.d. on days 0, 1, and 7, plus misoprostol 5 µg/kg orally b.i.d. on days 2 to 6). Clinical, haematological, biochemical, and ultrasonographic parameters were assessed on days 0, 7, and 14. The incidence of pyometra was 1.40%, with higher prevalence in middle-aged (5 to 9 years, 48.57%) and nulliparous (62.38%) dogs and breeds like Labrador Retriever (14.76%), Golden Retriever (10%), and Shih Tzu (10%). Group II showed significant reductions in mean uterine lumen diameter (from 23.21±3.556 mm to 8.21±0.710 mm, p